IDH1 and cholangiocarcinoma: Even if the response rate gained with ivosidenib is lower than what we see with other targeted therapies for advanced CCA (e.g., FGFR inhibitors [25, 26], with up to 42% ORR), our study confirms that the clinical benefit from IDH inhibition can be durable.